SCHEMBL6835367

SCHEMBL6835367

O=C(NCc1ccc(F)cc1)c1ccc2c(c1)C(=O)C(Cc1ccc(Cl)c(Cl)c1)[S+]([O-])N2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.44
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
PPARG P37231 1/20 0.43
MAOB P27338 1/20 0.42
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
SSTR3 P32745 3/20 0.40
CNR1 P21554 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
PTGER4 P35408 1/20 0.40
CCR2 P41597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6834773 0.94 MAPT (0.42) EPHX2PPARGLMNATP53MAPT
SCHEMBL6837223 0.94 PPARG (0.43) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL6834729 0.92 TP53 (0.44) PPARGLMNATP53MAPTCNR1
SCHEMBL6831840 0.90 TP53 (0.42) PPARGLMNATP53MAPTCNR1
SCHEMBL6835340 0.89 CNR1 (0.41) PPARGLMNATP53MAPTCNR1
SCHEMBL6835283 0.89 LMNA (0.47) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL6835302 0.88 MAPT (0.46) LMNATP53MAPTCNR1
SCHEMBL6835519 0.85 ALDH1A1 (0.44) EPHX2LMNAMAPTHSP90AA1HSP90AB1
SCHEMBL6835368 0.85 ALDH1A1 (0.44) EPHX2LMNAMAPTHSP90AA1HSP90AB1
SCHEMBL6834783 0.83 TSHR (0.40) EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 EPHX2 1812/4885HDAC4 367/4885HDAC1 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.